The work in the group focuses around studies of anticancer active drugs- and drug candidates and their interactions with DNA and RNA. We aim at identifying targets on DNA- or RNA-level that may facilitate the development of novel generations of highly efficient metal-based protocols for treatment of cancers. Current work in the group includes studies of platinum-, gold- and ruthenium-based anticancer active drugs and their influence on nucleic acid structure, transcription and protein translation. In a recently initiated project we are also investigating how short interfering RNAs (siRNA) might be used in combination with the metal-based drugs to optimize anticancer activity.

Principal investigator's in these groups: Sofi Elmroth.